Abstracts tagged "cytokines and systemic sclerosis"

Abstract Number: 36 • 2017 ACR/ARHP Annual Meeting
GM-CSF-Producing B Cells: A Novel B Cell Subset Involved in the Pathogenesis of Systemic Sclerosis
Kazuhiko Higashioka¹, Yuri Ota¹, Tsuyoshi Nakayama¹, Koji Mishima¹, Masahiro Ayano¹, Yasutaka Kimoto², Hiroki Mitoma¹, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi³ and Hiroaki Niro⁴, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Systemic sclerosis (SSc) is a T helper type 2 (Th2)-driven autoimmune disease characterized by vasculopathy and fibrosis. There are still unmet needs in the…
Abstract Number: 2980 • 2017 ACR/ARHP Annual Meeting
Chemokine CCL21 As a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Anna-Maria Hoffmann-Vold¹, Roger Hesselstrand², Håvard Fretheim¹, Thor Ueland¹, Arne K Andreassen¹, Oyvind Midtvedt¹, Torhild Garen¹, Pål Aukrust¹, John A Belperio³ and Øyvind Molberg¹, ¹Oslo University Hospital, Oslo, Norway, ²Lund University, Lund, Sweden, ³University of California, Los Angeles, Los Angeles, CA
Background/Purpose : Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles of chemokines CCL19/21 and their receptor…
Abstract Number: 3250 • 2016 ACR/ARHP Annual Meeting
Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis
Minghua Wu¹, Murray Baron², Marie Hudson³, Marvin J. Fritzler⁴, Claudia Pedroza⁵, Jun Ying¹, Gloria Salazar¹, Julio Charles⁶, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Pediatrics, University of Texas-McGovern Medical School, Houston, TX, ⁶Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Currently available clinical biomarkers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in the context of systemic sclerosis (SSc) A previous…
Abstract Number: 900 • 2015 ACR/ARHP Annual Meeting
A Multidimensional Immunomics Approach Annotates an Immunome Shaped By the Interplay Between the Periphery and the Skin Microenvironment in Systemic Sclerosis
Hari Balaji Venkatanarayanan^1,2, Andrea Low³, Raymond Ong Jr.⁴, Liyun Lai^1,2, Juntao Li^2,5, Chie Hwee Ang^1,2, Suzan Saidin^1,2, Camillus Chua^1,2, Jing Yao Leong^1,2, Agnieszka Maliszewska^1,2, Lakshmi Ramakrishna^1,2, Julian Thumboo⁶ and Salvatore Albani^1,2, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ³Division of Rheumatology, Singapore General Hospital, Singapore, Singapore, ⁴Singhealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, ⁵SingHealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, ⁶Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Systemic sclerosis (SSc), is a chronic autoimmune disorder of the connective tissue. There is an unmet need to define precise immune correlates involved in…
Abstract Number: 1914 • 2015 ACR/ARHP Annual Meeting
Oncostatin M As a Potential Molecular Target in Systemic Sclerosis
Maria Feeney¹, Farhat Syed², Korsa Khan³, Xu Shiwen⁴, Katherine Sully⁵, Sarah Trinder⁶, Paul Wilson⁷, David Abraham^6,8, Alan M. Holmes⁶ and Christopher P. Denton⁹, ¹Biopharm Research, GlaxoSmithKline, Stevenage, United Kingdom, ²Immuno-Inflammation, GlaxoSmithKline, Stevenage, United Kingdom, ³Centre For Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁴UCL Medical School, London, United Kingdom, ⁵Biopharm Translational Medicine, GlaxoSmithKline, Stevenage, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁷Quantitative Sciences, GlaxoSmithKline, Stevenage, United Kingdom, ⁸Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁹Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: Oncostatin M (OSM) is a pleiotropic member of the gp130/ IL-6 cytokine family, produced by a variety of immune cells, including macrophages, neutrophils…
Abstract Number: 1513 • 2012 ACR/ARHP Annual Meeting
TSLP Receptor Deficiency Reduces IL-13 Expression and Prevents Fibrosis in Experimental Scleroderma
Alicia Usategui¹, Vanessa Miranda¹, Gabriel Criado², Manuel J. Del Rey¹, Elena Izquierdo¹, Warren J. Leonard³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Laboratory of Molecular Immunology and Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive fibrosis of the skin and internal organs. Although SSc shares pathogenetic features with other…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].